drugset / Trial / NCT00782574
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase I study to assess the safety and tolerability of AZD2281 in combination with Cisplatin in patients with advanced Solid Tumours. This is an open label-dose finding; to establish the maximum tolerated dose of AZD2281 combined with Cisplatin in patients with advanced solid tumours. Approximately 50 (max 60) patients from 2 countries will be enrolled
Timeline
- Start
- 2008-11-12
- Primary completion
- 2012-02-01
- Completion
- 2023-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 100 mg | Oral |
| Subject | Olaparib | Small molecule | 200 mg | Oral |
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Background | Cisplatin | Other / unclassified | — | Intravenous |